ArriVent develops pharmaceutical products to cure presently untreatable cancer.
ArriVent has raised $250.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
ArriVent's investors include General Catalyst, HSG, Hillhouse Investment, Lilly Asia Ventures, Catalio Capital Management.
ArriVent is headquartered in Pennsylvania Furnace, United States.
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
ArriVent is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ArriVent — Funding & Investors." VCBacked, May 11, 2026, https://www.vcbacked.co/company/arrivent. Accessed July 19, 2026.
VCBacked. (2026). ArriVent — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/arrivent
{{cite web |title=ArriVent — Funding & Investors |url=https://www.vcbacked.co/company/arrivent |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated